No relation between cystic fibrosis-related diabetes and type 1 diabetes autoimmunity

Diabetes Care

Volumn 35, Issue 8, 2012, Pages

  Gottlieb, Peter A ^a   Yu, Liping ^a   Babu, Sunanda ^a   Wenzlau, Janet ^a   Bellin, Melena ^b   Frohnert, Brigitte I ^b   Moran, Antoinette ^b  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HLA ANTIGEN CLASS 2; INSULIN; INSULIN ANTIBODY; INSULINOMA ASSOCIATED PROTEIN 2 ANTIBODY; UNCLASSIFIED DRUG; ZINC TRANSPORTER 8 ANTIBODY;

ADOLESCENT; ADULT; ALLELE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; AUTOIMMUNITY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HLA SYSTEM; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LETTER; MAJOR CLINICAL STUDY; MALE; RADIOIMMUNOASSAY;

ADOLESCENT; ADULT; AUTOANTIBODIES; AUTOIMMUNITY; CYSTIC FIBROSIS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; FEMALE; HAPLOTYPES; HUMANS; INSULIN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84864382876     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2327     Document Type: Letter

References (3)

1. Yu L, Herold K, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab selectively suppresses specific islet antibodies. Diabetes 2011;60:2560-2565
2. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007;104:17040-17045 (Pubitemid 350210987)
3. Emery LM, Babu S, Bugawan TL, et al. Newborn HLA-DR,DQ genotype screening: ageand ethnicity-specific type 1 diabetes risk estimates. Pediatr Diabetes 2005;6:136-144 (Pubitemid 41223238)